SANUWAVE Health (SNWV) 10-Q 13 Dec 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	Dec. 08, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Registrant Name	SANUWAVE Health, Inc.
Entity Central Index Key	0001417663
Entity Address, State or Province	NV
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		481,619,621

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current Assets:
Cash	$ 96	$ 2,437
Accounts receivable, net of allowance for doubtful accounts of $475 in 2021 and $343 in 2020	1,727	2,356
Inventory	2,935	2,956
Prepaid expenses and other current assets	405	179
Total Current Assets	5,163	7,928
Property and Equipment, net	531	471
Right of Use Assets, net	685	795
Other Intangible Assets, net	6,369	6,545
Goodwill	7,260	7,260
Other Assets	271	28
Total Assets	20,279	23,027
Current Liabilities:
Senior secured promissory note payable, in default	10,903	10,676
Convertible promissory notes payable, in default	4,000	4,000
Convertible promissory notes, related parties, in default	1,596	1,596
Accounts payable	5,728	4,454
Accrued expenses	2,492	2,127
Accrued employee compensation	2,463	2,541
Warrant liability	6,191	8,855
Current portion of SBA loans	464	321
Accrued interest	981	1,021
Accrued interest, related parties	124	77
Current portion of lease liabilities	414	451
Current portion of contract liabilities	32	32
Other	0	23
Total Current Liabilities	35,388	36,174
Non-current Liabilities
SBA loans	1,033	143
Lease liabilities	319	391
Contract liabilities	156	37
Deferred tax liability	16	0
Total Non-current Liabilities	1,524	571
Total Liabilities	36,912	36,745
Contingencies
STOCKHOLDERS' DEFICIT
Preferred Stock, par value $0.001, 5,000,000 shares authorized; 6,175, 293, 90 and 8 shares designated Series A, Series B, Series C and Series D, respectively; no shares issued and outstanding at March 31, 2021 and December 31, 2020	0	0
Common Stock, par value $0.001, 800,000,000 shares authorized; 481,619,621 and 470,694,621 issued and outstanding at March 31, 2021 and December 31, 2020, respectively	482	471
Additional Paid-in Capital	144,582	142,563
Accumulated Deficit	(161,627)	(156,690)
Accumulated Other Comprehensive Loss	(70)	(62)
Total Stockholders' Deficit	(16,633)	(13,718)
Total Liabilities and Stockholders' Deficit	$ 20,279	$ 23,027

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current Assets:
Accounts receivable, allowance for doubtful accounts	$ 475	$ 343
STOCKHOLDERS' DEFICIT
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	800,000,000	800,000,000
Common stock, shares issued (in shares)	481,619,621	470,694,621
Common stock, shares outstanding (in shares)	481,619,621	470,694,621
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, shares authorized (in shares)	6,175	6,175
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, shares authorized (in shares)	293	293
Series C Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, shares authorized (in shares)	90	90
Series D Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, shares authorized (in shares)	8	8

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues:
Total Revenues	$ 2,116	$ 149
Cost of Revenues	1,055	130
Gross Margin	1,061	19
Operating Expenses:
Research and development	354	287
Selling and marketing	1,780	608
General and administrative	3,321	1,920
Total Operating Expenses	5,455	2,815
Operating Loss	(4,394)	(2,796)
Other Income (Expense), net
Change in fair value of warrant liability	635	0
Interest expense	(1,122)	(19)
Interest expense, related party	(47)	(183)
Loss on foreign currency exchange	7	(4)
Other Income (Expense), net	(527)	(206)
Net Loss before Income Taxes	(4,921)	(3,002)
Provision for Income Taxes	16	0
Net Loss	(4,937)	(3,002)
Other Comprehensive Loss
Foreign currency translation adjustments	(8)	5
Total Comprehensive Loss	$ (4,945)	$ (2,997)
Loss per Share:
Net loss per share - basic (in dollars per share)	$ (0.01)	$ (0.01)
Net loss per share - diluted (in dollars per share)	$ (0.01)	$ (0.01)
Weighted average shares outstanding - basic (in shares)	518,490,225	296,061,866
Weighted average shares outstanding - diluted (in shares)	518,490,225	296,061,866
Product [Member]
Revenues:
Total Revenues	$ 253	$ 75
Accessory and Parts Revenue [Member]
Revenues:
Total Revenues	1,825	63
License Fees and Other [Member]
Revenues:
Total Revenues	$ 38	$ 11

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Beginning balance at Dec. 31, 2019	$ 0	$ 294	$ 115,458	$ (125,752)	$ (62)	$ (10,062)
Beginning balance (in shares) at Dec. 31, 2019	0	293,780,400
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Proceeds from warrant exercise	$ 0	$ 1	9	0	0	10
Proceeds from warrant exercise (in shares)	0	1,000,000
Shares issued for services	$ 0	$ 1	199	0	0	200
Shares issued for services (in shares)	0	1,000,000
Stock-based compensation	$ 0	$ 0	21	0	0	21
Conversion of short term notes	$ 0	$ 2	262	0	0	264
Conversion of short term notes (in shares)	0	1,820,461
Conversion of advances from related parties	$ 0	$ 0	3	0	0	3
Conversion of advances from related parties (in shares)	0	62,811
Net loss	$ 0	$ 0	0	(3,002)	0	(3,002)
Foreign currency translation adjustment	0	0	0	0	4	4
Ending balance at Mar. 31, 2020	$ 0	$ 298	115,952	(128,754)	(58)	(12,562)
Ending balance (in shares) at Mar. 31, 2020	0	297,663,672
Beginning balance at Dec. 31, 2020	$ 0	$ 471	142,563	(156,690)	(62)	(13,718)
Beginning balance (in shares) at Dec. 31, 2020	0	470,694,621
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cashless warrant exercise	$ 0	$ 11	(11)	0	0	0
Cashless warrant exercise (in shares)	0	10,925,000
Reclassification of warrant liability due to cashless warrant exercise	$ 0	$ 0	2,030	0	0	2,030
Reclassification of warrant liability due to cashless warrant exercise (in shares)	0	0
Net loss	$ 0	$ 0	0	(4,937)	0	(4,937)
Foreign currency translation adjustment	0	0	0	0	(8)	(8)
Ending balance at Mar. 31, 2021	$ 0	$ 482	$ 144,582	$ (161,627)	$ (70)	$ (16,633)
Ending balance (in shares) at Mar. 31, 2021	0	481,619,621

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash Flows - Operating Activities:
Net loss	$ (4,937)	$ (3,002)
Adjustments to reconcile net loss to net cash used by operating activities
Amortization of intangibles	176	0
Depreciation	94	53
Bad debt expense	132	83
Share-based payment	0	222
Deferred taxes	16	0
Change in warrant valuation	(635)	0
Amortization of debt issuance costs and original issue discount	228	0
Accrued interest	(40)	2
Interest payable, related parties	47	183
Changes in operating assets and liabilities
Accounts receivable - trade	489	(111)
Inventory	21	24
Prepaid expenses	(444)	(104)
Other assets	(24)	(1)
Operating leases	(6)	(3)
Accounts payable	1,274	(323)
Accrued expenses	365	65
Accrued employee compensation	(78)	289
Contract liabilities	(22)	(23)
Net Cash Used by Operating Activities	(3,344)	(2,646)
Cash Flows - Investing Activities
Purchases of property and equipment	(101)	(5)
Net Cash Flows Used by Investing Activities	(101)	(5)
Cash Flows - Financing Activities
Proceeds from sale of convertible preferred stock	0	2,250
Proceeds from SBA loan	1,033	0
Proceeds from warrant exercise	0	10
Proceeds from related party deposits	125	0
Payments of principal on finance leases	(46)	(28)
Net Cash Flows Provided by Financing Activities	1,112	2,232
Effect of Exchange Rates on Cash	(8)	5
Net Change in Cash During Period	(2,341)	(414)
Cash at Beginning of Period	2,437	1,761
Cash at End of Period	96	1,347
Supplemental Information:
Cash paid for interest	934	0
Non-cash Investing and Financing Activities:
Cashless warrant exercise	2,030	0
Conversion of short-term notes payable to equity	0	264
Conversion of advance from related parties	0	2
Additions to right of use assets from new finance lease liabilities	$ 0	$ 128

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2021
Nature of the Business and Basis of Presentation [Abstract]
Nature of the Business and Basis of Presentation	1. Nature of the Business and Basis of Presentation SANUWAVE Health, Inc. and Subsidiaries (“SANUWAVE” or the “Company”) is focused on the research, development, and commercialization of its patented noninvasive and biological response activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. The Company’s lead regenerative product in the United States is the dermaPACE® device used for treating diabetic foot ulcers. Through the Company’s acquisition, on August 6, 2020, of the UltraMIST® assets from Celularity, Inc. (“Celularity”), SANUWAVE now combines two highly complementary and market-cleared energy transfer technologies and two human tissue biologic products, which creates a platform of scale with an end-to-end product offering in the advanced wound care market. Basis of Presentation – The accompanying unaudited Condensed Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these Condensed Consolidated Financial Statements do not include all the information and disclosures required by U.S. GAAP for comprehensive financial statements. The financial information as of and for the three months ended and 2020 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2021. The Condensed Consolidated Balance Sheet at December 31, 2020 has been derived from the audited Consolidated Financial Statements at that date but does not include all of the information and disclosures required by U.S. GAAP for comprehensive financial statements. These financial statements should be read in conjunction with the Company’s December 31, 2020 Annual Report on Form 10-K filed with the SEC on October 21, 2021 (the “2020 Annual Report”). Reclassifications – Covid-19 –

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2021
Going Concern [Abstract]
Going Concern	2. Going Concern Our recurring losses from operations and dependency upon future issuances of equity or other financing to fund ongoing operations have raised substantial doubt as to our ability to continue as a going concern. We will be required to raise additional funds to finance our operations and remain a going concern; we may not be able to do so, and/or the terms of any financings may not be advantageous to us. The continuation of our business is dependent upon raising additional capital. We expect to devote substantial resources for the commercialization of the dermaPACE system and will continue to research and develop the non-medical uses of the PACE technology, both of which will require additional capital resources. The operating losses and the events of default on the Company’s notes payable indicate substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the filing of this Form 10-Q. The continuation of our business is dependent upon raising additional capital to fund operations. Management’s plans are to obtain additional capital in 2022 through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the conversion of outstanding warrants, issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to our existing shareholders. In addition, there can be no assurances that our plans to obtain additional capital will be successful on the terms or timeline we expect, or at all. Although no assurances can be given, management believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for us. If these efforts are unsuccessful, we may be required to significantly curtail or discontinue operations or, if available, obtain funds through financing transactions with unfavorable terms. The accompanying Condensed Consolidated Financial Statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the Condensed Consolidated Financial Statements do not necessarily purport to represent realizable or settlement values. The Condensed Consolidated Financial Statements do not include any adjustment that might result from the outcome of this uncertainty. Our Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability of assets and classification of assets and liabilities that might be necessary should we be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Significant accounting policies followed by the Company are summarized below and should be read in conjunction with those described in Note 3 to the Consolidated Financial Statements in our 2020 Annual Report. Estimates Significant estimates include the recording of allowances for doubtful accounts, the net realizable value of inventory, useful lives of long-lived assets, fair value of goodwill and other intangible assets, the determination of the valuation allowances for deferred taxes and the estimated fair value of warrants. Concentration of credit risk and limited suppliers Major customers are defined as customers whose accounts receivable or sales individually consist of more than ten percent of total trade receivables or total sales, respectively. The percentage of accounts receivable and sales from major customers of the Company for the periods indicated were as follows: March 31, 2021 December 31, 2020 Accounts Receivable: Customer A 15 % 46 % Three Months Ended March 31, 2021 March 31, 2020 Revenue: Customer B n/a 66 % The Company currently purchases most of its product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. The percentage of purchases from major vendors of the Company that exceeded ten percent of total purchases for the three months ended March 31, 2021 and 2020 were as follows: Three Months Ended March 31, 2021 March 31, 2020 Purchases: Vendor A 55 % n/a Vendor B 13 % n/a Vendor C n/a 35 % Vendor D n/a 22 % Vendor E n/a 11 % Goodwill and Other Intangible Assets – Intangibles-Goodwill and Other the Company determined that intangible assets related to certain customer relationships was impaired. No additional impairment was indicated at March 31, 2021. Recent Accounting Pronouncements – Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In May 2021, the FASB issued ASU 2021-04, Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). In December 2019, the FASB issued ASU 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350) Simplifying the Test for Goodwill Impairment. The amendments in ASU 2017-04 modified the testing that an entity should perform for its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. This amendment is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2017-04 effective January 1, 2021. The adoption of this guidance did not impact our results of operations or financial position.

Loss per Share

Loss per Share	3 Months Ended
	Mar. 31, 2021
Loss per Share [Abstract]
Loss per Share	4. Loss per Share The net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares outstanding for the three months ended March 31, 2021 and 2020. In accordance with ASC Topic 260-10-45-13, Earnings Per Share 2021 2020 Weighted average shares outstanding Common shares 481,619,621 296,061,866 Common shares issuable assuming excercise of nominally priced warrants 36,870,604 - Weighted average shares outstanding 518,490,225 296,061,866 Diluted net loss per share would be computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding. To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net loss per share. As a result of the net loss for the three months ended March 31, 2021 and 2020, all potentially dilutive shares were anti-dilutive and therefore excluded from the computation of diluted net loss per share. Anti-dilutive equity securities consist of the following at March 31, 2021 and 2020, respectively: 2021 2020 Common stock options 31,864,385 34,403,385 Common stock purchase warrants 142,265,576 8,374,091 Convertible notes payable 60,328,907 - Short-term notes payable - 2,250,000 Convertible preferred stock - 16,071,429 234,458,868 61,098,905

Inventory

Inventory	3 Months Ended
	Mar. 31, 2021
Inventory [Abstract]
Inventory	5. Inventory Inventory consists of the following at March 31, 2021 and December 31, 2020 (in thousands): 2021 2020 Inventory - finished goods $ 2,270 $ 2,276 Inventory - parts and accessories 665 680 Total inventory $ 2,935 $ 2,956

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2021
Accrued Expenses [Abstract]
Accrued Expenses	6. Accrued Expenses Accrued expenses consist of the following at March 31, 2021 and December 31, 2020 (in thousands): 2021 2020 Outside services $ 191 $ 347 License fees 298 336 Board of director’s fees 380 320 Registration penalties 1,055 264 Commissions - 239 Legal and professional fees 139 197 Warranty reserve 180 180 Inventory purchases 72 91 Other 177 153 $ 2,492 $ 2,127 There was no activity in the warranty reserve during the three months ended March 31, 2021.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2021
Revenue [Abstract]
Revenue	7. Revenue Disaggregation of Revenue - Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 United States International Total United States International Total Product $ 41 $ 212 $ 253 $ 34 $ 41 $ 75 Accessories and parts 1,689 136 1,825 63 - 63 License fees and other 33 5 38 1 10 11 $ 1,763 $ 353 $ 2,116 $ 98 $ 51 $ 149 Contract liabilities - March 31, 2021 December 31, 2020 Service agreements $ 63 $ 69 Deposit on future equipment purchases 125 - Total contract liabilities 188 69 Less: current portion (32 ) (32 ) Non-current contract liabilities $ 156 $ 37 During the three months ended March 31, 2021 and 2020, the Company recognized revenue related to these contract liabilities of $8 thousand and $22 thousand, respectively, that were in the beginning contract liability balances for each of those periods.

Debt with Related Parties

Debt with Related Parties	3 Months Ended
	Mar. 31, 2021
Debt with Related Parties [Abstract]
Debt with Related Parties	8. Debt with Related Parties Debt with related parties at March 31, 2021 and December 31, 2020 consisted of the following (in thousands): 2021 2020 Maturity Date Stated Interest Rate Incremental Default Interest Convertible promissory notes (HealthTronics), related parties, in default $ 1,372 $ 1,372 In default 12.0 % +2.0 % Convertible promissory notes (Stolarski), related parties, in default 224 224 In default 12.0 % +2.0 % Total debt with related parties $ 1,596 $ 1,596 Convertible promissory notes payable (HealthTronics), in default – As the Seller Note (as defined in Note 9) was not repaid prior to January 1, 2021, HealthTronics may elect to convert the outstanding principal amount plus any accrued but unpaid interest thereon into shares of the Company’s common stock, at a conversion price of $0.10 per share. The Company evaluated embedded conversion features within the convertible promissory note and determined that the conversion feature does not require to be bifurcated. Upon adoption of ASC 2020-6 effective January 1, 2021, the convertible promissory note is accounted for as a single liability due to the elimination of the beneficial conversion feature accounting model. Convertible promissory notes payable (Stolarski), in default – As the Stolarski Note was not repaid prior to January 1, 2021, the holder may elect to convert the outstanding principal amount plus any accrued by unpaid interest thereon into shares of common stock at a conversion price of $0.10 per share. The Company evaluated embedded conversion features within the convertible promissory note and determined that the conversion feature does not require to be bifurcated. Upon adoption of ASC 2020-6 effective January 1, 2021, the convertible promissory note is accounted for as a single liability due to the elimination of the beneficial conversion feature accounting model.

Debt with Unaffiliated Parties

Debt with Unaffiliated Parties	3 Months Ended
	Mar. 31, 2021
Debt with Unaffiliated Parties [Abstract]
Debt with Unaffiliated Parties	9. Debt with Unaffiliated Parties Debt with unaffiliated parties at March 31, 2021 and December 31, 2020 consisted of the following (in thousands): 2021 2020 Maturity Date Stated Interest Rate Incremental Payment in Kind Interest Incremental Default Interest Senior secured promissory note payable, in default:: Principal $ 15,000 $ 15,000 Debt issuance costs (1,440 ) (1,520 ) Debt discount (2,657 ) (2,804 ) 10,903 10,676 In default 12.25 % +3.00 % +5.00 % Convertible promissory note payable, in default 4,000 4,000 In default 12.00 % n/a +5.00 % SBA loan #1 464 464 May 28, 2022 1.00 % n/a n/a SBA loan #2 1,033 - February 20, 2026 1.00 % n/a n/a 16,400 15,140 Less: current maturities including notes in default (15,367 ) (14,997 ) Debt with unafffiliated parties, long-term $ 1,033 $ 143 Senior secured promissory note payable, in default (“Senior Secured Note”) - The debt issuance costs and debt discount related to the Senior Secured Note were capitalized as a reduction in the principal amount and are being amortized to interest expense over the life of the Senior Secured Note. The amortization of the debt issuance costs and debt discount for the three months ended March 31, 2021 was $228 thousand and is included in interest expense. Accrued interest related to the Senior Secured Note was $666 thousand and $642 thousand at March 31, 2021 and December 31, 2020, respectively. Interest expense on the Senior Secured Note was $760 thousand for the three months ended March 31, 2021. Convertible promissory notes payable, in default (“Seller Note”) - The Company evaluated embedded conversion features within the convertible promissory note and determined that the conversion feature does not require to be bifurcated. Upon adoption of ASC 2020-6 effective January 1, 2021, the convertible promissory note is accounted for as a single liability due to the elimination of the beneficial conversion feature accounting model. SBA Loan #1 - SBA Loan #2 – All or a portion of SBA Loan #2 may be fully or partially forgiven by the SBA upon application by the Company not later than June 2022 in accordance with SBA regulations. The ultimate forgiveness of SBA Loan #2 is also contingent upon regulatory authorities concurring with management’s good faith assessment that the current economic uncertainty made the loan request necessary to support ongoing operations. If, despite the Company’s good-faith belief that given the circumstances the Company satisfied all eligibility requirements for SBA Loan #2, the Company is later determined to have violated any applicable laws or regulations or it is otherwise determined that the Company was ineligible to receive SBA Loan #2, the Company may be required to repay SBA Loan #2 in its entirety and/or be subject to additional penalties. In the event SBA Loan #2, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal. As of March 31, 2021, the entire $1,033 thousand loan balance outstanding is included in non-current liabilities in the accompanying Condensed Consolidated Balance Sheets.

Warrants

Warrants	3 Months Ended
	Mar. 31, 2021
Warrants [Abstract]
Warrants	10. Warrants A summary of the warrant activity during the three months ended March 31, 2021 is as follows: Warrant class Outstanding December 31, 2020 Exercised Outstanding March 31, 2021 Exercise price/share Expiration date Class E Warrants 141,091,485 - 141,091,485 $ 0.25 August 2023 Class O Warrants 909,091 - 909,091 0.11 January 2022 Class P Warrants 265,000 - 265,000 0.20 June 2024 LGH Warrant 35,000,000 (11,400,000 ) 23,600,000 0.01 June 2025 NH Expansion Warrant 13,091,160 - 13,091,160 0.01 August 2030 Total 190,356,736 (11,400,000 ) 178,956,736 On February 3, 2021, the Company issued 10,925,000 shares of its common stock to LGH upon the cashless exercise of 11,400,000 of the LGH Warrants under the terms of the warrant agreement. After this cashless exercise, 23,600,000 of LGH Warrants remain outstanding.

Warrant Liabilities

Warrant Liabilities	3 Months Ended
	Mar. 31, 2021
Warrant Liabilities [Abstract]
Warrant Liabilities	11. Warrant Liabilities A summary of the warrant liability activity for the three months ended March 31, 2021 is as follows: Warrants Outstanding Fair Value per Share Fair Value Balance December 31, 2020 48,091,160 $ 0.18 $ 8,855,379 Cashless exercise of LGH Warrants (11,400,000 ) 0.18 (2,030,025 ) Gain on remeasurement of warrant liability (634,672 ) Balance March 31, 2021 36,691,160 $ 0.17 $ 6,190,682 NH Expansion Warrants -- Black Scholes option pricing model March 31,2021 December 31, 2020 Exercise Price (1) $ 0.01 $ 0.01 Warrant Expiration Date (1) August 6, 2030 August 6, 2030 Interest Rate (annual) (2) 0.70 % 0.65 % Volatility (annual) (3) 145.04 % 143.94 % Time to Maturity (Years) 9.4 9.6 Calculated fair value per share $ 0.1700 $ 0.1891 ( 1) Based on the terms provided in the warrant agreement to purchase common stock of the Company dated August 6, 2020. (2) Interest rate for U.S. Treasury Bonds, as of each presented period ending date, as published by the U.S. Federal Reserve. (3) Based on the historical daily volatility of the Company as of each presented period ending date. LGH Warrants – Black Scholes option pricing model March 31, 2021 December 31, 2020 Exercise Price (1) $ 0.01 $ 0.01 Warrant Expiration Date (1) June 5, 2025 June 5, 2025 Interest Rate (annual) (2) 0.37 % 0.36 % Volatility (annual) (3) 100.16 % 99 % Time to Maturity (Years) 4.2 4.4 Calculated fair value per share $ 0.1680 $ 0.1823 (1) Based on the terms provided in the warrant agreement to purchase common stock of the Company dated August 6, 2020. (2) Interest rate for U.S. Treasury Bonds, as of each presented period ending date, as published by the U.S. Federal Reserve. (3) Based on the historical daily volatility of the Company as of each presented period ending date.

Leases

Leases	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Leases	12. Leases The following is a summary of the Company’s right of use assets and lease liabilities at March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 December 31, 2020 Operating Leases Financing Leases Total Operating Leases Financing Leases Total Right of use assets $ 725 $ 644 $ 1,369 $ 725 $ 644 $ 1,369 Less: Accumulated amortization (396 ) (288 ) (684 ) (339 ) (235 ) (574 ) Right of use assets, net $ 329 $ 356 $ 685 $ 386 $ 409 $ 795 Lease liabilities $ 352 $ 381 $ 733 $ 415 $ 427 $ 842 Less: current portion (214 ) (200 ) (414 ) (257 ) (194 ) (451 ) Lease Liabilities $ 138 $ 181 $ 319 $ 158 $ 233 $ 391 Total lease costs for the three months ended March 31, 2021 and 2020 are as follows (in thousands): 2021 2020 Finance lease costs: Amortization of right-of-use assets $ 53 $ 41 Interest on lease liabilities 13 12 Operating lease costs 83 52 Total lease costs $ 149 $ 105 The following summarizes cash paid for amounts included in the measurement of lease liabilities as well as the related right-of-use assets obtained for the three months ended March 31, 2021 and 2020 (in thousands): 2021 2020 Cash paid for amouonts included in measurement of lease liabilities: Operating cash flows from finance leases $ (59 ) $ (40 ) Operating cash flows from operating leases $ (83 ) $ (55 ) Operating Leases - Amount Year ending December 31, 2021 (remainder of year) $ 210 2022 94 2023 65 2024 8 2025 3 Total lease payments 380 Less: Present value adjustment (28 ) Lease liability $ 352 As of March 31, 2021, the Company’s operating leases had a weighted average remaining lease term of 1.9 years and a weighted average discount rate of 10.0%. Rent expense for the three months ended March 31, 2021 and 2020 was $83 thousand and $52 thousand, respectively. Financing Lease - Amount Year ending December 31, 2021 (remainder of year) $ 176 2022 200 2023 18 Total lease payments 394 Less: Present value adjustment (13 ) Lease liability $ 381 As of March31, 2021, the Company’s financing leases had a weighted average remaining lease term of 2.0 years based on annualized base payments expiring through 2023 and a weighted average discount rate of 13.2%. As of March 31, 2021, the Company did not have additional operating or financing leases that have yet commenced.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2021
Contingencies [Abstract]
Contingencies	13. Contingencies Supplier disputes - In May 2021, the Company received notification alleging that it is not in compliance with the license agreement with Celularity entered into in connection with the acquisition of the UltraMIST assets. The Company has responded and asserted that the Company is not in breach and that the supplier has breached various agreements. It is too early to determine the outcome of this matter. Any potential impact to the Company cannot be fully determined at this time and there is no guarantee that the dispute will be resolved in a manner beneficial to the Company or at all. As part of the Asset Purchase Agreement on August 6, 2020, the Company assumed obligations for a purchase order for UltraMIST devices from Celularity’s vendor Minnetronix. This purchase order had a remaining purchase commitment of approximately $1.1 million. The purchase order also calls for production delay fees of 1.25% of the committed inventory if the Company delays production. There is also a cancelation clause of 20% of the remaining balance in the event that the Company delays production for more than six months. On September 23, 2021, Minnetronix notified the Company that it was cancelling the purchase order for the UltraMIST devices as a result Company delaying production more than six months. This notification includes fees and charges for the cancellation of the purchase order of an additional $320 thousand. The Company expects to be able to resume production upon paying this obligation. While the Company is disputing certain aspects of this termination notice and is continuing to engage with Minnetronix regarding resolution of this matter, including reinstatement of the purchase order, there is no guarantee that the dispute will be resolved in a manner beneficial to the Company or at all.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	14. Related Party Transactions On February 13, 2018, the Company entered into an Agreement for Purchase and Sale, Limited Exclusive Distribution and Royalties, and Servicing and Repairs with Premier Shockwave Wound Care, Inc., a Georgia Corporation (“PSWC”), and Premier Shockwave, Inc., a Georgia Corporation (“PS”). Each of PS and PSWC is owned by A. Michael Stolarski, a member of the Company’s board of directors and an existing shareholder of the Company The agreement provides for the purchase by PSWC and PS of dermaPACE System and related equipment sold by the Company along with limited but exclusive distribution rights to provide dermaPACE Systems to certain governmental healthcare facilities and the agreement contains provisions whereby in the event of a change of control of the Company (as defined in the agreement), the stockholders of PSWC have the right and option to cause the Company to purchase all of the stock of PSWC, and whereby the Company has the right and option to purchase all issued and outstanding shares of PSWC, in each case based upon certain defined purchase price provisions and other terms. During the three months ended March 31, 2021 and 2020, the Company recorded $8 thousand and $13 thousand, respectively, in revenue from an entity owned by this related party. In addition, contract liabilities includes a balance of $63 thousand at March 31, 2021 and $69 thousand at December 31, 2020 from this related party. In March 2021, PSWC paid the Company $125 thousand as a deposit for future purchase of new medical equipment. Please see Note 16 – Subsequent Events in the accompanying Condensed Consolidated Financial Statements for discussion of advances from directors in October 2021.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Taxes [Abstract]
Income Taxes	15. Income Taxes The provision for income taxes of $16 thousand and deferred tax liability are related to the goodwill of $7.3 million recorded as part of the acquisition of the Celularity assets and is known as a “naked credit”. The goodwill was assigned an indefinite life for book purposes but is deductible for income tax purposes over a fifteen-year life. As a result, the deferred tax liability has an indefinite life and cannot be used as a source of taxable income to support the realization of other deferred tax assets.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events April 2021 Securities Purchase Agreement and Warrants (In default) - As noted above, on April 20, 2021, the Company issued the Leviston Note to the Purchaser in an aggregate principal amount of up to $3.4 million (the “Aggregate Amount”), which shall be advanced in disbursements by the Purchaser (“Leviston Disbursements”), as set forth in the Leviston Note. On May 14, 2021, the Leviston Note was amended to increase the Aggregate Amount to $4.2 million. On April 21, 2021, the Purchaser advanced a Leviston Disbursement of $750 thousand, which is net of an original issue discount of 8%. Subsequent to April 21, 2021 the Purchaser made two additional disbursements, net of 8% original issue discounts, totaling $1.0 million, $750 thousand on May 14, 2021 and $250 thousand on September 3, 2021. The remaining disbursements up to the Aggregate Amount are subject to the satisfaction of certain terms and conditions set forth in the Leviston Note. Leviston Disbursements bear an interest at a rate of five percent (5%) per annum and have a maturity date of twelve (12) months from the date of issuance. The Leviston Note is convertible at the option of the holder into shares of the common stock of the Company at a conversion price per share equal to the lesser of (i) $0.18, and (ii) ninety percent (90%) of the closing price for a share of common stock reported on the OTCQB on the effective date of the Registration Statement (as defined below). The Leviston Note contains customary events of default and covenants, including limitations on incurrences of indebtedness and liens. Pursuant to the Leviston Purchase Agreement, the Company has agreed, within a reasonable period of time following the Leviston Closing Date, and in any event prior to any Leviston Disbursement under the Leviston Note subsequent to the initial Leviston Disbursement, to enter into a security agreement in favor of the Leviston, securing the Company’s obligations under the Leviston Note. The rights of Leviston to receive payments under the Leviston Note are subordinate to the rights of North Haven Expansion pursuant to a subordination agreement, that the Company and Leviston entered into with North Haven Expansion on April 20, 2021, in connection with the Private Placement (the “Subordination Agreement”). In connection with the Leviston Purchase Agreement, the Company entered into a registration rights agreement with the Leviston on April 20, 2021 (the “Leviston Registration Rights Agreement”) pursuant to which the Company agreed to file a registration statement (the “Registration Statement”) with the SEC no later than thirty days following the Leviston Closing Date for the registration of 100% of the maximum number of the shares issuable upon conversion of the Leviston Note and exercise of the Leviston Warrants issued pursuant to the Leviston Purchase Agreement (the “Leviston Registrable Securities”). The Company shall use its best efforts to keep the Registration Statement continuously effective under the Securities Act of 1933, as amended (the “Securities Act”), until all Leviston Registrable Securities have been sold, or may be sold without the requirement to be in compliance with Rule 144(c)(1) of the Securities Act and otherwise without restriction or limitation pursuant to Rule 144 of the Securities Act, as determined by the counsel to the Company. The Company has yet to file the Registration Statement and, under the terms of the Leviston Registration Rights Agreement, it is obligated to pay in cash a one-time aggregate amount of $250 thousand to the holders of the Leviston Notes, plus 1% of the outstanding principal for each 30-day period during which the Company continues not to have in-place an effective Registration Statement. On August 31, 2021, Leviston notified the Company that it was in default of the Leviston Purchase Agreement effective June 11, 2021 for failure to timely file a Registration Statement. From the date of the default, interest on the amounts due to Leviston is calculated at the default interest rate of 15% in addition to the registration penalties stated above. June 2021 Accounts Receivable Factoring Agreement – September 2021 Securities Purchase Agreement and Warrants (In default) - Under the terms of the September 2021 Purchase Agreements, the aggregate principal amount of the September 2021 Notes of up to $543 thousand (the “Aggregate Amount”), may be advanced in disbursements by the September 2021 Purchasers (“September 2021 Purchasers Disbursements”), as set forth in the September 2021 Notes. The September 2021 Purchasers Disbursements bear an interest at a rate of five percent (5%) per annum and have a maturity date of twelve (12) months from the date of issuance. Each September 2021 Note is convertible at the option of the holder into shares of common stock of the Company at a conversion price per share equal to (A) until the date of effectiveness of the Registration Statement, $0.18 and (B) after the date of effectiveness of the Registration Statement, the lesser of (i) $0.18, (ii) ninety percent (90%) of the closing price for a share of common stock reported on the OTCQB on the effective date of the Registration Statement or (iii) 75% of the lowest volume weighted average price, as defined,, which shall be no lower than $0.01. The September 2021 Notes contain customary events of default and covenants, including limitations on incurrences of indebtedness and liens. Pursuant to each September 2021 Purchase Agreement, the Company entered into a security agreement in favor of the applicable September 2021 Purchaser, securing the Company’s obligations under the applicable September 2021 Note. The rights of each September 2021 Purchaser to receive payments under their respective note is subordinate to the rights of North Haven Expansion pursuant to a Subordination Agreement, that the Company and each September 2021 Purchaser entered into with North Haven Expansion in connection with the September 2021 Private Placement. In connection with each September 2021 Purchase Agreement, the Company entered into a registration rights agreement with the September 2021 Purchasers on September 3, 2021 (the “September 2021 Purchasers Registration Rights Agreement”) pursuant to which the Company has agreed to file a Registration Statement no later than ninety (90) days following the September 2021 Purchasers Closing Date for the registration of 100% of the maximum number of the shares issuable upon conversion of the September 2021 Notes and exercise of the September 2021 Warrants issued pursuant to such September 2021 Purchase Agreement (the “September 2021 Purchasers Registrable Securities”). The Company shall use its best efforts to keep the Registration Statement continuously effective under the Securities Act of 1933, as amended, until all September 2021 Purchasers Registrable Securities have been sold, or may be sold without the requirement to be in compliance with Rule 144(c)(1) of the Securities Act and otherwise without restriction or limitation pursuant to Rule 144 of the Securities Act, as determined by the counsel to the Company. The September 2021 Notes were in default as of October 25, 2021 and, accordingly, on that date, interest began accruing at the default rate of 15% in addition to registration penalties per the September 2021 Purchasers Registration Rights Agreement. The Company has yet to file the Registration Statement, and under the terms of the September 2021 Registration Rights Agreement, it is obligated to pay in cash a one-time aggregate amount of $250 thousand to the holders of the September 2021 Notes, plus 1% of the outstanding principal for each 30-day period during which the Company continues not to have in-place an effective Registration Statement. As a result of this breach of the September 2021 Registration Rights Agreement, interest on the September 2021 Notes accrues at the default interest rate of 15%. September 2021 Advances on Future Receipts Financing – October 2021 Advances from Directors - In exchange for the Nemelka Advance, the Company issued to NightWatch Capital Advisors, LLC a promissory note in the principal amount of $25 thousand (the “Nemelka Note”). The Nemelka Note matures on June 30, 2022 and accrues interest at a rate equal to 15.0% per annum. In exchange for the Stolarski Advance, as well as the $125 thousand deposit received in March 2021 by the Company (see Note 14), the Company issued to Mr. Stolarski a promissory note in the principal amount of $150 thousand (“Stolarski Note #2”). Stolarski Note #2 matures on June 30, 2022 and accrues interest at a rate equal to 15.0% per annum.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Summary of Significant Accounting Policies [Abstract]
Estimates	Estimates Significant estimates include the recording of allowances for doubtful accounts, the net realizable value of inventory, useful lives of long-lived assets, fair value of goodwill and other intangible assets, the determination of the valuation allowances for deferred taxes and the estimated fair value of warrants.
Concentration of credit risk and limited suppliers	Concentration of credit risk and limited suppliers Major customers are defined as customers whose accounts receivable or sales individually consist of more than ten percent of total trade receivables or total sales, respectively. The percentage of accounts receivable and sales from major customers of the Company for the periods indicated were as follows: March 31, 2021 December 31, 2020 Accounts Receivable: Customer A 15 % 46 % Three Months Ended March 31, 2021 March 31, 2020 Revenue: Customer B n/a 66 % The Company currently purchases most of its product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. The percentage of purchases from major vendors of the Company that exceeded ten percent of total purchases for the three months ended March 31, 2021 and 2020 were as follows: Three Months Ended March 31, 2021 March 31, 2020 Purchases: Vendor A 55 % n/a Vendor B 13 % n/a Vendor C n/a 35 % Vendor D n/a 22 % Vendor E n/a 11 %
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets – Intangibles-Goodwill and Other the Company determined that intangible assets related to certain customer relationships was impaired. No additional impairment was indicated at March 31, 2021.
Recent Accounting Pronouncements	Recent Accounting Pronouncements – Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In May 2021, the FASB issued ASU 2021-04, Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). In December 2019, the FASB issued ASU 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350) Simplifying the Test for Goodwill Impairment. The amendments in ASU 2017-04 modified the testing that an entity should perform for its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. This amendment is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2017-04 effective January 1, 2021. The adoption of this guidance did not impact our results of operations or financial position.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Summary of Significant Accounting Policies [Abstract]
Concentration of Credit Risk and Limited Suppliers	The percentage of accounts receivable and sales from major customers of the Company for the periods indicated were as follows: March 31, 2021 December 31, 2020 Accounts Receivable: Customer A 15 % 46 % Three Months Ended March 31, 2021 March 31, 2020 Revenue: Customer B n/a 66 % The percentage of purchases from major vendors of the Company that exceeded ten percent of total purchases for the three months ended March 31, 2021 and 2020 were as follows: Three Months Ended March 31, 2021 March 31, 2020 Purchases: Vendor A 55 % n/a Vendor B 13 % n/a Vendor C n/a 35 % Vendor D n/a 22 % Vendor E n/a 11 %

Loss per Share (Tables)

Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Loss per Share [Abstract]
Weighted Average Shares Outstanding	Accordingly, warrants issued with a $0.01 per share exercise price, are included in weighted average shares outstanding as follows: 2021 2020 Weighted average shares outstanding Common shares 481,619,621 296,061,866 Common shares issuable assuming excercise of nominally priced warrants 36,870,604 - Weighted average shares outstanding 518,490,225 296,061,866
Anti-dilutive Equity Securities	Anti-dilutive equity securities consist of the following at March 31, 2021 and 2020, respectively: 2021 2020 Common stock options 31,864,385 34,403,385 Common stock purchase warrants 142,265,576 8,374,091 Convertible notes payable 60,328,907 - Short-term notes payable - 2,250,000 Convertible preferred stock - 16,071,429 234,458,868 61,098,905

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2021
Inventory [Abstract]
Inventory	Inventory consists of the following at March 31, 2021 and December 31, 2020 (in thousands): 2021 2020 Inventory - finished goods $ 2,270 $ 2,276 Inventory - parts and accessories 665 680 Total inventory $ 2,935 $ 2,956

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2021
Accrued Expenses [Abstract]
Accrued Expenses	Accrued expenses consist of the following at March 31, 2021 and December 31, 2020 (in thousands): 2021 2020 Outside services $ 191 $ 347 License fees 298 336 Board of director’s fees 380 320 Registration penalties 1,055 264 Commissions - 239 Legal and professional fees 139 197 Warranty reserve 180 180 Inventory purchases 72 91 Other 177 153 $ 2,492 $ 2,127

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2021
Revenue [Abstract]
Disaggregation of Revenue	The following table presents revenue from contracts with customers for the three months ended March 31, 2021 and 2020 (in thousands): Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 United States International Total United States International Total Product $ 41 $ 212 $ 253 $ 34 $ 41 $ 75 Accessories and parts 1,689 136 1,825 63 - 63 License fees and other 33 5 38 1 10 11 $ 1,763 $ 353 $ 2,116 $ 98 $ 51 $ 149
Contract Liabilities	As of March 31, 2021 and December 31, 2020, the Company has contract liabilities from contracts with customers as follows (in thousands): March 31, 2021 December 31, 2020 Service agreements $ 63 $ 69 Deposit on future equipment purchases 125 - Total contract liabilities 188 69 Less: current portion (32 ) (32 ) Non-current contract liabilities $ 156 $ 37

Debt with Related Parties (Tabl

Debt with Related Parties (Tables)	3 Months Ended
	Mar. 31, 2021
Debt with Related Parties [Abstract]
Debt with Related Parties	Debt with related parties at March 31, 2021 and December 31, 2020 consisted of the following (in thousands): 2021 2020 Maturity Date Stated Interest Rate Incremental Default Interest Convertible promissory notes (HealthTronics), related parties, in default $ 1,372 $ 1,372 In default 12.0 % +2.0 % Convertible promissory notes (Stolarski), related parties, in default 224 224 In default 12.0 % +2.0 % Total debt with related parties $ 1,596 $ 1,596

Debt with Unaffiliated Parties

Debt with Unaffiliated Parties (Tables)	3 Months Ended
	Mar. 31, 2021
Debt with Unaffiliated Parties [Abstract]
Debt with Unaffiliated Parties	Debt with unaffiliated parties at March 31, 2021 and December 31, 2020 consisted of the following (in thousands): 2021 2020 Maturity Date Stated Interest Rate Incremental Payment in Kind Interest Incremental Default Interest Senior secured promissory note payable, in default:: Principal $ 15,000 $ 15,000 Debt issuance costs (1,440 ) (1,520 ) Debt discount (2,657 ) (2,804 ) 10,903 10,676 In default 12.25 % +3.00 % +5.00 % Convertible promissory note payable, in default 4,000 4,000 In default 12.00 % n/a +5.00 % SBA loan #1 464 464 May 28, 2022 1.00 % n/a n/a SBA loan #2 1,033 - February 20, 2026 1.00 % n/a n/a 16,400 15,140 Less: current maturities including notes in default (15,367 ) (14,997 ) Debt with unafffiliated parties, long-term $ 1,033 $ 143

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2021
Warrants [Abstract]
Warrant Activity	A summary of the warrant activity during the three months ended March 31, 2021 is as follows: Warrant class Outstanding December 31, 2020 Exercised Outstanding March 31, 2021 Exercise price/share Expiration date Class E Warrants 141,091,485 - 141,091,485 $ 0.25 August 2023 Class O Warrants 909,091 - 909,091 0.11 January 2022 Class P Warrants 265,000 - 265,000 0.20 June 2024 LGH Warrant 35,000,000 (11,400,000 ) 23,600,000 0.01 June 2025 NH Expansion Warrant 13,091,160 - 13,091,160 0.01 August 2030 Total 190,356,736 (11,400,000 ) 178,956,736

Warrant Liabilities (Tables)

Warrant Liabilities (Tables)	3 Months Ended
	Mar. 31, 2021
Warrant Liabilities [Abstract]
Warrant Activity	A summary of the warrant liability activity for the three months ended March 31, 2021 is as follows: Warrants Outstanding Fair Value per Share Fair Value Balance December 31, 2020 48,091,160 $ 0.18 $ 8,855,379 Cashless exercise of LGH Warrants (11,400,000 ) 0.18 (2,030,025 ) Gain on remeasurement of warrant liability (634,672 ) Balance March 31, 2021 36,691,160 $ 0.17 $ 6,190,682
Fair Value of Warrant Liabilities Using Black-Scholes Model	Significant Black Scholes valuation model inputs related to the NH Expansion Warrants at March 31, 2021 and December 31, 2020 are as follows: Black Scholes option pricing model March 31,2021 December 31, 2020 Exercise Price (1) $ 0.01 $ 0.01 Warrant Expiration Date (1) August 6, 2030 August 6, 2030 Interest Rate (annual) (2) 0.70 % 0.65 % Volatility (annual) (3) 145.04 % 143.94 % Time to Maturity (Years) 9.4 9.6 Calculated fair value per share $ 0.1700 $ 0.1891 ( 1) Based on the terms provided in the warrant agreement to purchase common stock of the Company dated August 6, 2020. (2) Interest rate for U.S. Treasury Bonds, as of each presented period ending date, as published by the U.S. Federal Reserve. (3) Based on the historical daily volatility of the Company as of each presented period ending date. Significant inputs into the model at March 31, 2021 and December 31, 2020 are as follows: Black Scholes option pricing model March 31, 2021 December 31, 2020 Exercise Price (1) $ 0.01 $ 0.01 Warrant Expiration Date (1) June 5, 2025 June 5, 2025 Interest Rate (annual) (2) 0.37 % 0.36 % Volatility (annual) (3) 100.16 % 99 % Time to Maturity (Years) 4.2 4.4 Calculated fair value per share $ 0.1680 $ 0.1823 (1) Based on the terms provided in the warrant agreement to purchase common stock of the Company dated August 6, 2020. (2) Interest rate for U.S. Treasury Bonds, as of each presented period ending date, as published by the U.S. Federal Reserve. (3) Based on the historical daily volatility of the Company as of each presented period ending date.

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Summary of ROU Assets and Lease Liabilities	The following is a summary of the Company’s right of use assets and lease liabilities at March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 December 31, 2020 Operating Leases Financing Leases Total Operating Leases Financing Leases Total Right of use assets $ 725 $ 644 $ 1,369 $ 725 $ 644 $ 1,369 Less: Accumulated amortization (396 ) (288 ) (684 ) (339 ) (235 ) (574 ) Right of use assets, net $ 329 $ 356 $ 685 $ 386 $ 409 $ 795 Lease liabilities $ 352 $ 381 $ 733 $ 415 $ 427 $ 842 Less: current portion (214 ) (200 ) (414 ) (257 ) (194 ) (451 ) Lease Liabilities $ 138 $ 181 $ 319 $ 158 $ 233 $ 391
Lease Costs	Total lease costs for the three months ended March 31, 2021 and 2020 are as follows (in thousands): 2021 2020 Finance lease costs: Amortization of right-of-use assets $ 53 $ 41 Interest on lease liabilities 13 12 Operating lease costs 83 52 Total lease costs $ 149 $ 105
Cash Paid for Amounts Included in Measurement of Lease Liabilities	The following summarizes cash paid for amounts included in the measurement of lease liabilities as well as the related right-of-use assets obtained for the three months ended March 31, 2021 and 2020 (in thousands): 2021 2020 Cash paid for amouonts included in measurement of lease liabilities: Operating cash flows from finance leases $ (59 ) $ (40 ) Operating cash flows from operating leases $ (83 ) $ (55 )
Operating Leases, Maturities	As of March 31, 2021, the maturities of the Company’s operating lease liability, which have initial or remaining lease terms in excess of one year, consist of the following (in thousands): Amount Year ending December 31, 2021 (remainder of year) $ 210 2022 94 2023 65 2024 8 2025 3 Total lease payments 380 Less: Present value adjustment (28 ) Lease liability $ 352
Finance Lease, Maturities	As of March 31, 2021, the maturities of the Company’s financing lease liability, which have initial or remaining lease terms in excess of one year, consist of the following (in thousands): Amount Year ending December 31, 2021 (remainder of year) $ 176 2022 200 2023 18 Total lease payments 394 Less: Present value adjustment (13 ) Lease liability $ 381

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation (Details) $ in Thousands	Aug. 06, 2020Product	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)
Nature of the Business and Basis of Presentation [Abstract]
Number of energy transfer technology products | Product	2
Number of human tissues biological products | Product	2
Reclassifications [Abstract]
Total revenues		$ 2,116	$ 149
Depreciation expense		94	53
Accessory and Parts Revenue [Member]
Reclassifications [Abstract]
Total revenues		$ 1,825	63
Reclassification, Other [Member] | Accessory and Parts Revenue [Member]
Reclassifications [Abstract]
Total revenues			63
Reclassification, Other [Member] | Rental Devices [Member]
Reclassifications [Abstract]
Depreciation expense			$ 41

Summary of Significant Accoun_4

Summary of Significant Accounting Policies, Concentration of Credit Risk and Limited Suppliers (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer A [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage	15.00%		46.00%
Revenue [Member] | Customer Concentration Risk [Member] | Customer B [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage		66.00%
Purchases [Member] | Supplier Concentration Risk [Member] | Vendor A [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage	55.00%
Purchases [Member] | Supplier Concentration Risk [Member] | Vendor B [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage	13.00%
Purchases [Member] | Supplier Concentration Risk [Member] | Vendor C [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage		35.00%
Purchases [Member] | Supplier Concentration Risk [Member] | Vendor D [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage		22.00%
Purchases [Member] | Supplier Concentration Risk [Member] | Vendor E [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage		11.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies, Goodwill and Other Intangible Assets (Details)	3 Months Ended
	Mar. 31, 2021
Customer Relationships [Member]
Goodwill and Other Intangible Assets
Useful life	7 years
Intellectual Property [Member]
Goodwill and Other Intangible Assets
Useful life	19 years

Loss per Share, Weighted Averag

Loss per Share, Weighted Average Shares Outstanding (Details) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Weighted Average Shares Outstanding [Abstract]
Weighted average shares outstanding (in shares)	518,490,225	296,061,866
Warrant exercise price (in dollars per share)	$ 0.01
Common Shares [Member]
Weighted Average Shares Outstanding [Abstract]
Weighted average shares outstanding (in shares)	481,619,621	296,061,866
Common Shares Issuable Assuming Exercise of Nominally Priced Warrants [Member]
Weighted Average Shares Outstanding [Abstract]
Weighted average shares outstanding (in shares)	36,870,604	0

Loss per Share, Anti Dilutive E

Loss per Share, Anti Dilutive Equity Securities (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	234,458,868	61,098,905
Common Stock Options [Member]
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	31,864,385	34,403,385
Common Stock Purchase Warrants [Member]
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	142,265,576	8,374,091
Convertible Notes Payable [Member]
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	60,328,907	0
Short-Term Notes Payable [Member]
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	0	2,250,000
Convertible Preferred Stock [Member]
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	0	16,071,429

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020
Inventory, Net [Abstract]
Inventory - finished goods	$ 2,270		$ 2,276
Inventory - parts and accessories	665		680
Total inventory	$ 2,935	$ 2,956	$ 2,956

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Accrued Expense [Abstract]
Outside services	$ 191	$ 347
License fees	298	336
Board of director's fees	380	320
Registration penalties	1,055	264
Commissions	0	239
Legal and professional fees	139	197
Warranty reserve	180	180
Inventory purchases	72	91
Other	177	153
Total accrued expenses	2,492	$ 2,127
Warranty reserve accrual	$ 0

Revenue, Disaggregation of Reve

Revenue, Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disaggregation of Revenue [Abstract]
Revenues	$ 2,116	$ 149
Product [Member]
Disaggregation of Revenue [Abstract]
Revenues	253	75
Accessories and Parts [Member]
Disaggregation of Revenue [Abstract]
Revenues	1,825	63
License Fees and Other [Member]
Disaggregation of Revenue [Abstract]
Revenues	38	11
United States [Member]
Disaggregation of Revenue [Abstract]
Revenues	1,763	98
United States [Member] | Product [Member]
Disaggregation of Revenue [Abstract]
Revenues	41	34
United States [Member] | Accessories and Parts [Member]
Disaggregation of Revenue [Abstract]
Revenues	1,689	63
United States [Member] | License Fees and Other [Member]
Disaggregation of Revenue [Abstract]
Revenues	33	1
International [Member]
Disaggregation of Revenue [Abstract]
Revenues	353	51
International [Member] | Product [Member]
Disaggregation of Revenue [Abstract]
Revenues	212	41
International [Member] | Accessories and Parts [Member]
Disaggregation of Revenue [Abstract]
Revenues	136	0
International [Member] | License Fees and Other [Member]
Disaggregation of Revenue [Abstract]
Revenues	$ 5	$ 10

Revenue, Contract Liabilities (

Revenue, Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Contract liabilities [Abstract]
Total contract liabilities	$ 188		$ 69
Less: current portion	(32)		(32)
Non-current contract liabilities	156		37
Revenue related to contract liabilities	8	$ 22
Service Agreement [Member]
Contract liabilities [Abstract]
Total contract liabilities	63		69
Deposit on Future Equipment Purchases [Member]
Contract liabilities [Abstract]
Total contract liabilities	$ 125		$ 0

Debt with Related Parties, Summ

Debt with Related Parties, Summary (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Due to Related Parties, Current [Abstract]
Convertible promissory notes, related parties, in default	$ 1,596	$ 1,596
Total debt with related parties	1,596	1,596
Health Tronics [Member]
Due to Related Parties, Current [Abstract]
Convertible promissory notes, related parties, in default	$ 1,372	1,372
Maturity date	In default
Stated interest rate	12.00%
Incremental default interest	2.00%
A. Michael Stolarski [Member]
Due to Related Parties, Current [Abstract]
Convertible promissory notes, related parties, in default	$ 224	$ 224
Maturity date	In default
Stated interest rate	12.00%
Incremental default interest	2.00%

Debt with Related Parties, Conv

Debt with Related Parties, Convertible Promissory Notes Payable (HealthTronics), in Default (Details) - Health Tronics [Member] - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2021	Aug. 06, 2020
Convertible Notes Payable Related Parties [Abstract]
Interest rate	12.00%
Convertible Note [Member]
Convertible Notes Payable Related Parties [Abstract]
Principal amount		$ 1.4
Maturity date	Aug. 6, 2021
Accrued Interest Rate		2.00%
Interest rate		12.00%
Common stock conversion price (in dollars per share)		$ 0.10

Debt with Related Parties, Co_2

Debt with Related Parties, Convertible Promissory Notes Payable (Stolarski), in Default (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Aug. 06, 2020
Convertible Note [Abstract]
Accrued interest, related parties	$ 124	$ 77
A. Michael Stolarski [Member]
Convertible Note [Abstract]
Interest rate	12.00%
A. Michael Stolarski [Member] | Convertible Note [Member]
Convertible Note [Abstract]
Principal amount			$ 223
Maturity date	Aug. 6, 2021
Accrued Interest Rate			2.00%
Interest rate			12.00%
Accrued interest, related parties	$ 17	$ 11
Common stock conversion price (in dollars per share)			$ 0.10

Debt with Unaffiliated Parties,

Debt with Unaffiliated Parties, Summary (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Feb. 20, 2021	Dec. 31, 2020
Senior Secured Promissory Notes Payable [Abstract]
Senior secured promissory note payable, in default	$ 10,903		$ 10,676
Convertible promissory note payable, in default	4,000		4,000
Due with unaffiliated current	16,400		15,140
Less: current maturities including notes in default	(15,367)		(14,997)
Debt with unaffiliated parties, long-term	1,033		143
SBA Loan #1 [Member]
Senior Secured Promissory Notes Payable [Abstract]
SBA loans	$ 464		464
Maturity date	May 28, 2022
Stated interest rate	1.00%
Incremental payment in kind interest
Incremental default interest
SBA Loan #2 [Member]
Senior Secured Promissory Notes Payable [Abstract]
SBA loans	$ 1,033		0
Maturity date	Feb. 20, 2026
Stated interest rate	1.00%	1.00%
Incremental payment in kind interest
Incremental default interest
Senior Secured Note [Member]
Senior Secured Promissory Notes Payable [Abstract]
Principal amount	$ 15,000		15,000
Debt issuance costs	(1,440)		(1,520)
Debt discount	(2,657)		(2,804)
Senior secured promissory note payable, in default	$ 10,903		10,676
Maturity date	In default
Stated interest rate	12.25%
Incremental payment in kind interest	0.0300
Incremental default interest	5.00%
Convertible Debt [Member]
Senior Secured Promissory Notes Payable [Abstract]
Convertible promissory note payable, in default	$ 4,000		$ 4,000
Maturity date	In default
Stated interest rate	12.00%
Incremental payment in kind interest
Incremental default interest	5.00%

Debt with Unaffiliated Partie_2

Debt with Unaffiliated Parties, Senior Secured Promissory Note Payable, in Default (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Aug. 06, 2020
Senior Secured Promissory Notes Payable [Abstract]
Accrued interest	$ 981		$ 1,021
Interest expense	$ 1,122	$ 19
Senior Secured Note and Warrants [Member] | NH Expansion Credit Fund Holdings LP [Member]
Senior Secured Promissory Notes Payable [Abstract]
Principal amount				$ 15,000
Additional default accrued interest rate	5.00%
Senior Secured Note [Member]
Senior Secured Promissory Notes Payable [Abstract]
Principal amount	$ 15,000		15,000
Senior Secured Note [Member] | NH Expansion Credit Fund Holdings LP [Member]
Senior Secured Promissory Notes Payable [Abstract]
Amortization expense	228
Accrued interest	666		$ 642
Interest expense	$ 760

Debt with Unaffiliated Partie_3

Debt with Unaffiliated Parties, Convertible Promissory Notes Payable, in Default (Details) - USD ($) $ in Thousands	Aug. 06, 2020	Mar. 31, 2021	Dec. 31, 2020
Debt Instruments [Abstract]
Accrued interest		$ 981	$ 1,021
Celularity's UltraMIST Assets [Member] | Seller Note [Member]
Debt Instruments [Abstract]
Paid for assets	$ 24,000
Issuance of promissory notes	$ 4,000
Maturity date		Aug. 6, 2021
Accrued Interest Rate	5.00%
Interest rate percentage	12.00%
Accrued interest		$ 312	$ 192

Debt with Unaffiliated Partie_4

Debt with Unaffiliated Parties, SBA Loans (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Aug. 27, 2021	Feb. 20, 2021	Dec. 31, 2020
SBA Loan #1 [Member]
SBA Loans [Abstract]
SBA loan classified as current	$ 464			$ 320
SBA loan classified as non-current				$ 142
Debt maturity date	May 28, 2022
Interest rate	1.00%
SBA Loan #1 [Member] | Subsequent Event [Member]
SBA Loans [Abstract]
Forgiveness of loan, principal amount		$ 454
Forgiveness of loan, interest amount		$ 6
SBA Loan #2 [Member]
SBA Loans [Abstract]
Proceeds from PPP loan			$ 1,030
SBA loan classified as non-current	$ 1,033
Debt maturity date	Feb. 20, 2026
Interest rate	1.00%		1.00%
Frequency of payment	monthly
Term of covered period	168 days
Term of deferment period	10 months

Warrants, Summary of Warrant Ac

Warrants, Summary of Warrant Activity (Details) - $ / shares	Feb. 03, 2021	Aug. 06, 2020	Mar. 31, 2021
Warrant Class [Roll Forward]
Outstanding, beginning (in shares)			190,356,736
Exercised (in shares)			(11,400,000)
Outstanding, ending (in shares)			178,956,736
Exercise price/share (in dollars per share)			$ 0.01
Class E Warrants [Member]
Warrant Class [Roll Forward]
Outstanding, beginning (in shares)			141,091,485
Exercised (in shares)			0
Outstanding, ending (in shares)			141,091,485
Exercise price/share (in dollars per share)			$ 0.25
Expiration date			Aug. 1, 2023
Class O Warrants [Member]
Warrant Class [Roll Forward]
Outstanding, beginning (in shares)			909,091
Exercised (in shares)			0
Outstanding, ending (in shares)			909,091
Exercise price/share (in dollars per share)			$ 0.11
Expiration date			Jan. 1, 2022
Class P Warrants [Member]
Warrant Class [Roll Forward]
Outstanding, beginning (in shares)			265,000
Exercised (in shares)			0
Outstanding, ending (in shares)			265,000
Exercise price/share (in dollars per share)			$ 0.20
Expiration date			Jun. 1, 2024
LGH Warrant [Member]
Warrant Class [Roll Forward]
Outstanding, beginning (in shares)			35,000,000
Exercised (in shares)		(35,000,000)	(11,400,000)
Outstanding, ending (in shares)	23,600,000		23,600,000
Exercise price/share (in dollars per share)			$ 0.01
Expiration date			Jun. 1, 2025
Issued (in shares)	10,925,000
NH Expansion Warrant [Member]
Warrant Class [Roll Forward]
Outstanding, beginning (in shares)			13,091,160
Exercised (in shares)			0
Outstanding, ending (in shares)			13,091,160
Exercise price/share (in dollars per share)			$ 0.01
Expiration date			Aug. 1, 2030

Warrant Liabilities (Details)

Warrant Liabilities (Details)		Aug. 06, 2020shares	Jun. 05, 2020shares	Mar. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares
Warrant Outstanding and Fair Value [Abstract]
Warrants outstanding (in shares) | shares				36,691,160	48,091,160
Cashless exercise of LGH Warrants (in shares) | shares				(11,400,000)
Fair value per share (in dollars per share)				$ 0.17	$ 0.18
Fair Value, Warrant Liability [Abstract]
Warrant Liability, Fair Value | $				$ 6,190,682	$ 8,855,379
Gain on measurement of warrant liability | $				$ (634,672)
Warrant Binomial Assumptions [Abstract]
Exercise Price (in dollars per share)				$ 0.01
NH Expansion Warrants [Member]
Warrant Outstanding and Fair Value [Abstract]
Cashless exercise of LGH Warrants (in shares) | shares				0
Warrant Binomial Assumptions [Abstract]
Exercise Price (in dollars per share)				$ 0.01
Warrant Expiration Date				Aug. 1, 2030
NH Expansion Warrants [Member] | Measurement Input, Exercise Price [Member]
Warrant Binomial Assumptions [Abstract]
Exercise Price (in dollars per share)	[1]			$ 0.01	$ 0.01
NH Expansion Warrants [Member] | Measurement Input, Warrant Expiration Date [Member]
Warrant Binomial Assumptions [Abstract]
Warrant Expiration Date	[1]			Aug. 6, 2030	Aug. 6, 2030
NH Expansion Warrants [Member] | Measurement Input, Interest Rate (annual) [Member]
Warrant Binomial Assumptions [Abstract]
Warrants and Rights Outstanding, Measurement Input	[2]			0.0070	0.0065
NH Expansion Warrants [Member] | Measurement Input, Volatility (annual) [Member]
Warrant Binomial Assumptions [Abstract]
Warrants and Rights Outstanding, Measurement Input	[3]			1.4504	1.4394
NH Expansion Warrants [Member] | Measurement Input, Time to Maturity [Member]
Warrant Binomial Assumptions [Abstract]
Time to Maturity (Years)				9 years 4 months 24 days	9 years 7 months 6 days
NH Expansion Warrants [Member] | Measurement Input, Calculated fair value per share [Member]
Warrant Binomial Assumptions [Abstract]
Stock Price (in dollars per share)				$ 0.1700	$ 0.1891
LGH Warrant [Member]
Warrant Outstanding and Fair Value [Abstract]
Cashless exercise of LGH Warrants (in shares) | shares		(35,000,000)		(11,400,000)
Cashless exercise of LGH Warrants. Fair value per share (in dollars per share)				$ 0.18
Fair Value, Warrant Liability [Abstract]
Cashless exercise of LGH Warrants, Fair Value | $				$ (2,030,025)
Warrant Binomial Assumptions [Abstract]
Exercise Price (in dollars per share)				$ 0.01
Warrant Expiration Date				Jun. 1, 2025
Warrant Liabilities [Abstract]
Warrants to purchase additional common stock (in shares) | shares			1,075,000
LGH Warrant [Member] | Measurement Input, Exercise Price [Member]
Warrant Binomial Assumptions [Abstract]
Exercise Price (in dollars per share)	[1]			$ 0.01	$ 0.01
LGH Warrant [Member] | Measurement Input, Warrant Expiration Date [Member]
Warrant Binomial Assumptions [Abstract]
Warrant Expiration Date	[1]			Jun. 5, 2025	Jun. 5, 2025
LGH Warrant [Member] | Measurement Input, Interest Rate (annual) [Member]
Warrant Binomial Assumptions [Abstract]
Warrants and Rights Outstanding, Measurement Input	[2]			0.0037	0.0036
LGH Warrant [Member] | Measurement Input, Volatility (annual) [Member]
Warrant Binomial Assumptions [Abstract]
Warrants and Rights Outstanding, Measurement Input	[3]			1.0016	0.99
LGH Warrant [Member] | Measurement Input, Time to Maturity [Member]
Warrant Binomial Assumptions [Abstract]
Time to Maturity (Years)				4 years 2 months 12 days	4 years 4 months 24 days
LGH Warrant [Member] | Measurement Input, Calculated fair value per share [Member]
Warrant Binomial Assumptions [Abstract]
Stock Price (in dollars per share)				$ 0.1680	$ 0.1823
[1]	Based on the terms provided in the warrant agreement to purchase common stock of the Company dated August 6, 2020.
[2]	Interest rate for U.S. Treasury Bonds, as of each presented period ending date, as published by the U.S. Federal Reserve.
[3]	Based on the historical daily volatility of the Company as of each presented period ending date

Leases, ROU Assets and Lease Li

Leases, ROU Assets and Lease Liability (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Operating Leases [Abstract]
Right of use assets	$ 725	$ 725
Less: Accumulated amortization	(396)	(339)
Right of use assets, net	329	386
Lease liability - right of use	352	415
Less: current portion	(214)	(257)
Lease liabilities	138	158
Financing Leases [Abstract]
Right of use assets	644	644
Less: Accumulated amortization	(288)	(235)
Right of use assets, net	356	409
Lease liability	381	427
Less: current portion	(200)	(194)
Lease liabilities	181	233
Total [Abstract]
Right of use assets	1,369	1,369
Less: Accumulated amortization	(684)	(574)
Right of use assets, net	685	795
Lease Liabilities	733	842
Less: current portion	(414)	(451)
Lease liabilities	$ 319	$ 391

Leases, Lease Costs (Details)

Leases, Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Finance lease costs [Abstract]
Amortization of right-of-use assets	$ 53	$ 41
Interest on lease liabilities	13	12
Operating lease costs	83	52
Total lease costs	$ 149	$ 105

Leases, Cash Paid for Amounts I

Leases, Cash Paid for Amounts Included in Measurement of Lease Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Cash paid for amounts included in measurement of lease liabilities [Abstract]
Operating cash flows from finance leases	$ (59)	$ (40)
Operating cash flows from operating leases	$ (83)	$ (55)

Leases, Operating Leases, Remai

Leases, Operating Leases, Remaining Lease Terms (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Maturities of Lease Liability - right of use [Abstract]
2021 (remainder of year)	$ 210
2022	94
2023	65
2024	8
2025	3
Total lease payments	380
Less: Present value adjustment	(28)
Lease liability	$ 352	$ 415
Weighted average remaining lease term, operating lease	1 year 10 months 24 days
Weighted average discount rate, operating lease	10.00%
Rent expense	$ 83	$ 52

Leases, Finance Lease, Remainin

Leases, Finance Lease, Remaining Lease Terms (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Maturities of Finance Lease Liability [Abstract]
2021 (remainder of year)	$ 176
2022	200
2023	18
Total lease payments	394
Less: Present value adjustment	(13)
Lease liability	$ 381	$ 427
Weighted average remaining lease term, finance lease	2 years
Weighted average discount rate, finance lease	13.20%

Contingencies (Details)

Contingencies (Details) - UltraMIST Devices [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Sep. 23, 2021	Aug. 06, 2020
Contingencies [Abstract]
Purchase order of remaining commitment			$ 1,100
Percentage of production delay fees			1.25%
Percentage of cancelation clause of remaining balance			20.00%
Minimum [Member]
Contingencies [Abstract]
Period of delaying production	6 months
Subsequent Event [Member]
Contingencies [Abstract]
Additional amount of fees and charges for cancellation of purchase order		$ 320

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Related Party Transaction Disclosures [Abstract]
Contract liabilities	$ 188		$ 69
A. Michael Stolarski [Member]
Related Party Transaction Disclosures [Abstract]
Revenues from related party	8	$ 13
Contract liabilities	63		$ 69
Deposits for future purchase of medical equipment	$ 125

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Taxes [Abstract]
Provision for Income Taxes	$ 16	$ 0
UltraMIST Devices [Member]
Income Taxes [Abstract]
Provision for Income Taxes	16
Goodwill	$ 7,300
Period of goodwill for income tax deductible purpose	15 years

Subsequent Events, April 2021 S

Subsequent Events, April 2021 Securities Purchase Agreement and Warrants (in Default) (Details) $ / shares in Units, $ in Thousands	Sep. 03, 2021USD ($)	Aug. 31, 2021	May 14, 2021USD ($)	Apr. 21, 2021USD ($)$ / shares	Apr. 20, 2021USD ($)$ / sharesshares	Sep. 03, 2021USD ($)Disbursement	Mar. 31, 2021$ / shares
Subsequent Event [Abstract]
Warrant exercise price (in dollars per share) | $ / shares							$ 0.01
Forecast [Member] | April 2021 Securities Purchase Agreement and Warrants [Member]
Subsequent Event [Abstract]
Principal amount			$ 4,200
Proceeds from, promissory note disbursement	$ 250		$ 750			$ 1,000
Number of additional disbursements | Disbursement						2
Default interest rate		15.00%
Subsequent Event [Member] | April 2021 Securities Purchase Agreement and Warrants [Member]
Subsequent Event [Abstract]
Principal amount					$ 3,400
Warrants to purchase additional common stock (in shares) | shares					16,666,667
Warrant exercise price (in dollars per share) | $ / shares					$ 0.18
Warrants term period					4 years
Proceeds from, promissory note disbursement				$ 750
Original issue discount rate				8.00%
Promissory note disbursement, interest rate				5.00%
Promissory note maturity term				12 months
Common stock conversion price per share (in dollars per share) | $ / shares				$ 0.18
Common stock conversion price percentage				90.00%

Subsequent Events, June 2021 Ac

Subsequent Events, June 2021 Accounts Receivable Factoring Agreement (Details) - USD ($) $ in Thousands	Jun. 17, 2021	Mar. 31, 2021	Dec. 31, 2020
Subsequent Event [Abstract]
Accounts receivable		$ 1,727	$ 2,356
Forecast [Member] | June 2021 Accounts Receivable Factoring Agreement [Member]
Subsequent Event [Abstract]
Percentage of accounts receivable	86.25%
Agreement term	1 month
Automatic renewal period of agreement	1 month
Period of notice termination	30 days
Forecast [Member] | June 2021 Accounts Receivable Factoring Agreement [Member] | Maximum [Member]
Subsequent Event [Abstract]
Accounts receivable	$ 3,000

Subsequent Events, September 20

Subsequent Events, September 2021 Securities Purchase Agreement and Warrants (in Default) (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 03, 2021	Mar. 31, 2021
Subsequent Event [Abstract]
Warrant exercise price (in dollars per share)		$ 0.01
Forecast [Member] | September 2021 Securities Purchase Agreement and Warrants [Member]
Subsequent Event [Abstract]
Warrants to purchase additional common stock (in shares)	2,777,779
Warrant exercise price (in dollars per share)	$ 0.18
Warrants term period	5 years
Promissory note disbursement, interest rate	5.00%
Promissory note maturity term	12 months
Common stock conversion price per share (in dollars per share)	$ 0.18
Common stock conversion price percentage	90.00%
Common stock conversion volume-weighted price percentage	75.00%
Default interest rate	15.00%
Forecast [Member] | September 2021 Securities Purchase Agreement and Warrants [Member] | Maximum [Member]
Subsequent Event [Abstract]
Principal amount	$ 543
Common stock conversion price per share (in dollars per share)	$ 0.01

Subsequent Events, September _2

Subsequent Events, September 2021 Advances on Future Receipts Financing (Details) $ in Thousands	Sep. 27, 2021USD ($)wkPayment	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Subsequent Event [Abstract]
Initial liability		$ 36,912	$ 36,745
Forecast [Member] | September 2021 Advances on Future Receipts Financing [Member]
Subsequent Event [Abstract]
Cash proceeds	$ 703
Sale of future receipts	$ 1,000
Non-recourse agreement term | wk	24
Minimum amount of receipts, payment	$ 59
Number of payments occurring at closing | Payment	4
Initial liability	$ 763
Debt discount	$ 60

Subsequent Events, October 2021

Subsequent Events, October 2021 Advances from Directors (Details) - USD ($) $ in Thousands	Oct. 27, 2021	Mar. 31, 2021	Mar. 31, 2021	Mar. 31, 2020
Subsequent Event [Abstract]
Proceeds from related party deposits			$ 125	$ 0
A. Michael Stolarski [Member]
Subsequent Event [Abstract]
Interest rate		12.00%	12.00%
October 2021 Advances from Directors [Member] | A. Michael Stolarski [Member]
Subsequent Event [Abstract]
Proceeds from related party deposits		$ 125
Forecast [Member] | October 2021 Advances from Directors [Member]
Subsequent Event [Abstract]
Advances from related parties	$ 50
Forecast [Member] | October 2021 Advances from Directors [Member] | NightWatch Capital Advisors, LLC [Member]
Subsequent Event [Abstract]
Advances from related parties	25
Principal amount	$ 25
Maturity date	Jun. 30, 2022
Interest rate	15.00%
Forecast [Member] | October 2021 Advances from Directors [Member] | A. Michael Stolarski [Member]
Subsequent Event [Abstract]
Advances from related parties	$ 25
Principal amount	$ 150
Maturity date	Jun. 30, 2022
Interest rate	15.00%